Dr. Martin on Patient Preferences With MCL Treatment

Peter Martin, MD
Published: Friday, May 05, 2017



Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses preferences patients have for treatment of their mantle cell lymphoma (MCL).

Intensive treatment regimens for patients with MCL, which are not often preferred, include high-dose cytarabine followed by autologous stem cell transplantation. This regimen does have high efficacy rates and induce remission durations for up to 10 years.

The challenge, however, is that this treatment requires patients to take off of work for approximately 6 months. Depending on their age, this is not an ideal or feasible situation, Martin explains. Patients would likely prefer to receive treatments that are broadly applicable and available in the community setting.


Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses preferences patients have for treatment of their mantle cell lymphoma (MCL).

Intensive treatment regimens for patients with MCL, which are not often preferred, include high-dose cytarabine followed by autologous stem cell transplantation. This regimen does have high efficacy rates and induce remission durations for up to 10 years.

The challenge, however, is that this treatment requires patients to take off of work for approximately 6 months. Depending on their age, this is not an ideal or feasible situation, Martin explains. Patients would likely prefer to receive treatments that are broadly applicable and available in the community setting.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x